FDA warning letter tells Clorox to clean up Aplicare plant

The FDA has issued a warning letter to a Clorox Aplicare plant in Connecticut raising concerns about sterility of its wound products. Image: Aplicare

The FDA says the unit of Clorox that manufactures povidone-iodine drug products needs to clean a big mess at a plant in Meriden, Connecticut, which failed to follow steps to insure the sterility of its wound products—products that the FDA also said are “unapproved.”

The agency last week posted a warning letter for the Aplicare plant that followed an inspection that ran from Dec. 15, 2015, to Jan. 15, 2016. The letter said that while the products are advertised as being for the “disinfection of wounds or burns,” or as a “preparation of skin and mucous membranes prior to surgery or injections,” the plant failed to implement adequate microbial controls.

The investigators found that the facility had not validated its sterilization process to ensure it worked. Since 2012, testing has repeatedly found samples of povidone-Iodine solution, swabsticks and sponges that were contaminated with microorganism like bacillus licheniformis, the letter said. It added notes regarding air handling issues and the plant's stability testing.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Finally, the FDA said that some of its products are unapproved because they do not comply with the FDA’s OTC Final Monograph for Topical Antifungal Drug Products. The FDA told Aplicare it would do well to hire a consultant that could help it meet FDA standards and improve processes like its handling of out of specification results.

Iodine product makers have run into regulatory concerns before. In 2015, French inspectors turned up contamination issues at a Chinese plant that manufactured iodine.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.